Bridge Biotherapeutics (Korea) Performance
| 288330 Stock | KRW 4,050 445.00 9.90% |
On a scale of 0 to 100, Bridge Biotherapeutics holds a performance score of 3. The firm shows a Beta (market volatility) of -0.87, which signifies possible diversification benefits within a given portfolio. As the market becomes more bullish, returns on owning Bridge Biotherapeutics are expected to decrease slowly. On the other hand, during market turmoil, Bridge Biotherapeutics is expected to outperform it slightly. Please check Bridge Biotherapeutics' mean deviation, downside deviation, standard deviation, as well as the relationship between the semi deviation and coefficient of variation , to make a quick decision on whether Bridge Biotherapeutics' price patterns will revert.
Risk-Adjusted Performance
3 of 100
Weak | Strong |
Insignificant
Compared to the overall equity markets, risk-adjusted returns on investments in Bridge Biotherapeutics are ranked lower than 3 (%) of all global equities and portfolios over the last 90 days. Despite somewhat weak basic indicators, Bridge Biotherapeutics sustained solid returns over the last few months and may actually be approaching a breakup point. ...more
| Total Cashflows From Investing Activities | 2 B |
Bridge |
Bridge Biotherapeutics Relative Risk vs. Return Landscape
If you would invest 386,000 in Bridge Biotherapeutics on September 27, 2024 and sell it today you would earn a total of 19,000 from holding Bridge Biotherapeutics or generate 4.92% return on investment over 90 days. Bridge Biotherapeutics is generating 0.4117% of daily returns and assumes 8.4591% volatility on return distribution over the 90 days horizon. Simply put, 75% of stocks are less volatile than Bridge, and 92% of all equity instruments are likely to generate higher returns than the company over the next 90 trading days. Expected Return |
| Risk |
Bridge Biotherapeutics Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Bridge Biotherapeutics' investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Bridge Biotherapeutics, and traders can use it to determine the average amount a Bridge Biotherapeutics' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0487
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | 288330 | |||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns |
Estimated Market Risk
| 8.46 actual daily | 75 75% of assets are less volatile |
Expected Return
| 0.41 actual daily | 8 92% of assets have higher returns |
Risk-Adjusted Return
| 0.05 actual daily | 3 97% of assets perform better |
Based on monthly moving average Bridge Biotherapeutics is performing at about 3% of its full potential. If added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Bridge Biotherapeutics by adding it to a well-diversified portfolio.
Bridge Biotherapeutics Fundamentals Growth
Bridge Stock prices reflect investors' perceptions of the future prospects and financial health of Bridge Biotherapeutics, and Bridge Biotherapeutics fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Bridge Stock performance.
| Return On Equity | -75.4 | |||
| Current Valuation | 29.26 B | |||
| Revenue | 1.92 B | |||
| EBITDA | (21.27 B) | |||
| Cash And Equivalents | 8.2 B | |||
| Total Debt | 53.63 M | |||
| Cash Flow From Operations | (21.13 B) | |||
| Total Asset | 46.66 B | |||
About Bridge Biotherapeutics Performance
By analyzing Bridge Biotherapeutics' fundamental ratios, stakeholders can gain valuable insights into Bridge Biotherapeutics' financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Bridge Biotherapeutics has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Bridge Biotherapeutics has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
Bridge Biotherapeutics, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. The company was founded in 2015 and is headquartered in Seongnam, Korea. BRIDGE BIOTHERAPEUTICS is traded on Korean Securities Dealers Automated Quotations in South Korea.Things to note about Bridge Biotherapeutics performance evaluation
Checking the ongoing alerts about Bridge Biotherapeutics for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Bridge Biotherapeutics help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Bridge Biotherapeutics had very high historical volatility over the last 90 days | |
| The company reported the revenue of 1.92 B. Net Loss for the year was (26.28 B) with loss before overhead, payroll, taxes, and interest of (1.12 B). | |
| Bridge Biotherapeutics has accumulated about 8.2 B in cash with (21.13 B) of positive cash flow from operations. | |
| Roughly 30.0% of the company shares are owned by insiders or employees |
- Analyzing Bridge Biotherapeutics' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Bridge Biotherapeutics' stock is overvalued or undervalued compared to its peers.
- Examining Bridge Biotherapeutics' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Bridge Biotherapeutics' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Bridge Biotherapeutics' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Bridge Biotherapeutics' stock. These opinions can provide insight into Bridge Biotherapeutics' potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Bridge Stock analysis
When running Bridge Biotherapeutics' price analysis, check to measure Bridge Biotherapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bridge Biotherapeutics is operating at the current time. Most of Bridge Biotherapeutics' value examination focuses on studying past and present price action to predict the probability of Bridge Biotherapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bridge Biotherapeutics' price. Additionally, you may evaluate how the addition of Bridge Biotherapeutics to your portfolios can decrease your overall portfolio volatility.
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Insider Screener Find insiders across different sectors to evaluate their impact on performance | |
| Portfolio Backtesting Avoid under-diversification and over-optimization by backtesting your portfolios | |
| Theme Ratings Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance |